Clinical Trial Update: Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating immunologic effects of CDX-301 and CDX-1140 in resectable pancreatic cancer has been terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• CDX-1140
• CDX-301

Snippet

Sponsor: Washington University School of Medicine | Conditions: Pancreatic Cancer, Cancer of the Pancreas | Phase 2 | Status: TERMINATED | Results posted: 2024-10-08